Do analysts prefer SCLX or LFCR?

Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 43.17%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, analysts plainly believe Lifecore Biomedical is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lifecore Biomedical 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, SCLX or LFCR?

Lifecore Biomedical has higher revenue and earnings than Scilex. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scilex $30.25M 1.52 -$358.73M -$49.70 N/A Lifecore Biomedical $128.87M 1.33 -$40.50M -$1.07 N/A

Is SCLX or LFCR more profitable?

Lifecore Biomedical has a net margin of -29.93% compared to Scilex's net margin of -1,414.57%. Company Net Margins Return on Equity Return on Assets Scilex -1,414.57% N/A -147.00% Lifecore Biomedical -29.93% N/A -16.16%

Do analysts prefer SCLX or RFAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, SCLX or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than Scilex. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scilex $30.25M 1.52 -$358.73M -$49.70 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Is SCLX or RFAI more profitable?

RF Acquisition Corp II has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Company Net Margins Return on Equity Return on Assets Scilex -1,414.57% N/A -147.00% RF Acquisition Corp II N/A N/A N/A

Does the media favor SCLX or RFAI?

In the previous week, RF Acquisition Corp II had 3 more articles in the media than Scilex. MarketBeat recorded 6 mentions for RF Acquisition Corp II and 3 mentions for Scilex. Scilex's average media sentiment score of 0.51 beat RF Acquisition Corp II's score of 0.15 indicating that Scilex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scilex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive RF Acquisition Corp II 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MENS or SCLX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, MENS or SCLX?

Jyong Biotech has higher earnings, but lower revenue than Scilex. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Scilex $30.25M 1.52 -$358.73M -$49.70 N/A

Is MENS or SCLX more profitable?

Jyong Biotech has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Scilex -1,414.57% N/A -147.00%

Do analysts rate SCLX or UNCY?

Unicycive Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 256.46%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Unicycive Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Do analysts rate SCLX or NRXP?

NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 871.83%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NRx Pharmaceuticals 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43

Is SCLX or NRXP more profitable?

NRx Pharmaceuticals has a net margin of -691.81% compared to Scilex's net margin of -1,414.57%. Company Net Margins Return on Equity Return on Assets Scilex -1,414.57% N/A -147.00% NRx Pharmaceuticals -691.81% N/A -63.92%

Does the media prefer SCLX or NRXP?

In the previous week, NRx Pharmaceuticals had 15 more articles in the media than Scilex. MarketBeat recorded 18 mentions for NRx Pharmaceuticals and 3 mentions for Scilex. Scilex's average media sentiment score of 0.51 beat NRx Pharmaceuticals' score of -0.30 indicating that Scilex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scilex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Scilex (SCLX) Competitors

$5.43 -0.14 (-2.51%)

As of 08/28/2026 04:00 PM Eastern

Compare

SCLX vs. LFCR, RFAI, MENS, UNCY, and NRXP

Should you buy Scilex stock or one of its competitors? Scilex's main competitors and comparable companies include Lifecore Biomedical (LFCR), RF Acquisition Corp II (RFAI), Jyong Biotech (MENS), Unicycive Therapeutics (UNCY), and NRx Pharmaceuticals (NRXP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Scilex compare to Lifecore Biomedical?

Scilex (NASDAQ:SCLX) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Lifecore Biomedical has higher revenue and earnings than Scilex. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.52	-$358.73M	-$49.70	N/A
Lifecore Biomedical	$128.87M	1.33	-$40.50M	-$1.07	N/A

Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 43.17%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, analysts plainly believe Lifecore Biomedical is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

69.7% of Scilex shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Scilex has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Lifecore Biomedical has a net margin of -29.93% compared to Scilex's net margin of -1,414.57%.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,414.57%	N/A	-147.00%
Lifecore Biomedical	-29.93%	N/A	-16.16%

In the previous week, Scilex had 2 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Scilex and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Scilex's score of 0.51 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Scilex	Positive
Lifecore Biomedical	Very Positive

Summary

Lifecore Biomedical beats Scilex on 11 of the 15 factors compared between the two stocks.

How does Scilex compare to RF Acquisition Corp II?

Scilex (NASDAQ:SCLX) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

RF Acquisition Corp II has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,414.57%	N/A	-147.00%
RF Acquisition Corp II	N/A	N/A	N/A

69.7% of Scilex shares are owned by institutional investors. 4.5% of Scilex shares are owned by company insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

RF Acquisition Corp II has lower revenue, but higher earnings than Scilex.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.52	-$358.73M	-$49.70	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

In the previous week, RF Acquisition Corp II had 3 more articles in the media than Scilex. MarketBeat recorded 6 mentions for RF Acquisition Corp II and 3 mentions for Scilex. Scilex's average media sentiment score of 0.51 beat RF Acquisition Corp II's score of 0.15 indicating that Scilex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
RF Acquisition Corp II	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RF Acquisition Corp II beats Scilex on 4 of the 7 factors compared between the two stocks.

How does Scilex compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Jyong Biotech has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Scilex	-1,414.57%	N/A	-147.00%

Jyong Biotech has higher earnings, but lower revenue than Scilex.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Scilex	$30.25M	1.52	-$358.73M	-$49.70	N/A

69.7% of Scilex shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Scilex had 2 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for Scilex and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Scilex's score of 0.51 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Jyong Biotech	Very Positive
Scilex	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jyong Biotech has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market. Comparatively, Scilex has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.

Summary

Jyong Biotech beats Scilex on 5 of the 9 factors compared between the two stocks.

How does Scilex compare to Unicycive Therapeutics?

Scilex (NASDAQ:SCLX) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Unicycive Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,414.57%	N/A	-147.00%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Scilex has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Unicycive Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 256.46%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

69.7% of Scilex shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 4.5% of Scilex shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Unicycive Therapeutics has lower revenue, but higher earnings than Scilex. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.52	-$358.73M	-$49.70	N/A
Unicycive Therapeutics	$680K	215.43	-$26.56M	-$1.75	N/A

In the previous week, Scilex had 2 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 3 mentions for Scilex and 1 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 1.87 beat Scilex's score of 0.51 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Scilex	Positive
Unicycive Therapeutics	Very Positive

Summary

Unicycive Therapeutics beats Scilex on 11 of the 16 factors compared between the two stocks.

How does Scilex compare to NRx Pharmaceuticals?

Scilex (NASDAQ:SCLX) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

69.7% of Scilex shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

NRx Pharmaceuticals has lower revenue, but higher earnings than Scilex. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.52	-$358.73M	-$49.70	N/A
NRx Pharmaceuticals	$3.39M	45.29	-$28.62M	-$0.55	N/A

NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 871.83%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, NRx Pharmaceuticals had 15 more articles in the media than Scilex. MarketBeat recorded 18 mentions for NRx Pharmaceuticals and 3 mentions for Scilex. Scilex's average media sentiment score of 0.51 beat NRx Pharmaceuticals' score of -0.30 indicating that Scilex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NRx Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

NRx Pharmaceuticals has a net margin of -691.81% compared to Scilex's net margin of -1,414.57%.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,414.57%	N/A	-147.00%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

Scilex has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

Summary

NRx Pharmaceuticals beats Scilex on 11 of the 15 factors compared between the two stocks.

Get Scilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCLX vs. The Competition

Export

Metric	Scilex	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$46.12M	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-0.11	787.65	273.16	25.45
Price / Sales	1.52	789.00	640.19	89.89
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	-0.15	11.97	12.98	6.14
Net Income	-$358.73M	$2.83B	$3.48B	$348.86M
7 Day Performance	-5.24%	0.39%	0.13%	-0.80%
1 Month Performance	-17.73%	5.34%	7.08%	4.13%
1 Year Performance	-69.43%	6.05%	24.67%	15.17%

Scilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCLX Scilex	0.8752 of 5 stars	$5.43 -2.5%	N/A	-69.4%	$46.12M	$30.25M	N/A	80	News Coverage Upcoming Earnings Analyst Downgrade
LFCR Lifecore Biomedical	2.4643 of 5 stars	$4.71 +3.6%	$6.50 +37.9%	-40.3%	$178.44M	$128.87M	N/A	690	Positive News Analyst Downgrade Gap Down
RFAI RF Acquisition Corp II	0.9708 of 5 stars	$50.05 -1.9%	N/A	+391.7%	$175.66M	N/A	N/A	N/A	Short Interest Increase Gap Down
MENS Jyong Biotech	N/A	$2.24 +0.7%	N/A	-95.7%	$170.76M	N/A	N/A	31	Positive News
UNCY Unicycive Therapeutics	3.2227 of 5 stars	$5.43 +1.7%	$18.75 +245.3%	+25.5%	$151.67M	N/A	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCLX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scilex (SCLX) Competitors

SCLX vs. LFCR, RFAI, MENS, UNCY, and NRXP

How does Scilex compare to Lifecore Biomedical?

Summary

How does Scilex compare to RF Acquisition Corp II?

Summary

How does Scilex compare to Jyong Biotech?

Summary

How does Scilex compare to Unicycive Therapeutics?

Summary

How does Scilex compare to NRx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX vs. The Competition

Scilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scilex (SCLX) Competitors

SCLX vs. LFCR, RFAI, MENS, UNCY, and NRXP

How does Scilex compare to Lifecore Biomedical?

Which has preferable earnings and valuation, SCLX or LFCR?

Do analysts prefer SCLX or LFCR?

Do institutionals and insiders believe in SCLX or LFCR?

Which has more risk & volatility, SCLX or LFCR?

Is SCLX or LFCR more profitable?

Does the media prefer SCLX or LFCR?

Summary

How does Scilex compare to RF Acquisition Corp II?

Is SCLX or RFAI more profitable?

Do insiders & institutionals hold more shares of SCLX or RFAI?

Do analysts prefer SCLX or RFAI?

Which has preferable earnings and valuation, SCLX or RFAI?

Does the media favor SCLX or RFAI?

Summary

How does Scilex compare to Jyong Biotech?

Is MENS or SCLX more profitable?

Which has better earnings and valuation, MENS or SCLX?

Do insiders & institutionals have more ownership in MENS or SCLX?

Does the media refer more to MENS or SCLX?

Do analysts recommend MENS or SCLX?

Which has more volatility and risk, MENS or SCLX?

Summary

How does Scilex compare to Unicycive Therapeutics?

Is SCLX or UNCY more profitable?

Which has more volatility & risk, SCLX or UNCY?

Do analysts rate SCLX or UNCY?

Do insiders and institutionals hold more shares of SCLX or UNCY?

Which has stronger valuation and earnings, SCLX or UNCY?

Does the media prefer SCLX or UNCY?

Summary

How does Scilex compare to NRx Pharmaceuticals?

Do insiders & institutionals hold more shares of SCLX or NRXP?

Which has stronger earnings and valuation, SCLX or NRXP?

Do analysts rate SCLX or NRXP?

Does the media prefer SCLX or NRXP?

Is SCLX or NRXP more profitable?

Which has more volatility and risk, SCLX or NRXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX vs. The Competition

Scilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools